Report cover image

Rare Disease Clinical Trials Market - 2024-2033

Publisher DataM Intelligence 4Market Research LLP
Published Mar 09, 2026
Length 182 Pages
SKU # DTAM21122359

Description

Rare Disease Clinical Trials Market Overview:
The Rare Disease Clinical Trials Market was valued at US$ 13.43 Billion in 2024 and is anticipated to reach US$ 30.13 Billion by 2033, at a CAGR of 0.0939 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Rare Disease Clinical Trials Market.

This report delivers a comprehensive overview of the Rare Disease Clinical Trials Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Rare Disease Clinical Trials Market. The Rare Disease Clinical Trials Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

Rare Disease Clinical Trials Market Scope:
By Clinical Trials Phase
• Phase I
• Phase II
• Phase III
• Phase IV

By Therapeutic Area
• Oncology
• Neurology
• Genetic Disorders
• Hematology
• Metabolic Disorders
• Immunology
• Others

By Study Design
• Interventional
• Observational
• Expanded Access
• Registry-based

By Sponsor
• Pharmaceutical Companies
• Biotechnology Companies
• Contract Research Organizations (CROs)
• Academic & Medical Research Institutes
• Government & Public Health Organizations
• Patient Advocacy Organizations

By Patient Recruitment
• Hospital-based
• Patient Registry
• Digital & Social Media
• Community-based
• Telehealth-enabled

By Innovation
• Biomarker based
• Genomic based
• Precision Medicine based
• Cell & Gene Therapy based
• Regenerative Medicine based
• Proteomics based
• Metabolomics based
• Others

Key Players
• Takeda Pharmaceutical Company Limited
• F. Hoffmann-La Roche Ltd.
• Pfizer Inc.
• AstraZeneca
• Novartis AG
• Labcorp
• IQVIA
• ICON plc
• Parexel International (MA) Corporation
• Syneos Health

Major Highlights
This report delivers a comprehensive overview of the Rare Disease Clinical Trials Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Rare Disease Clinical Trials Market. The Rare Disease Clinical Trials Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
South America (Colombia, Brazil, Argentina, Rest of South America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification
Increase Your Customer Base by 3X using our Partner Identification tool
Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?
• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

182 Pages
1. Definition and Overview
1.1. Study Objectives
1.2. Market Definition
1.3. Market Scope
1.4. Stakeholder Analysis
1.5. Currency Considered
1.6. Study Period
2. Executive Summary
2.1. Key Takeaways
2.2. Top To Bottom Analysis
2.3. Market Share Analysis
2.4. Data Points from Key Primary Interviews
2.5. Data Points from Key Secondary Databases
2.6. Market Snapshot
2.7. Geographical Snapshot
3. Dynamics
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising prevalence and improved diagnosis of rare diseases globally
3.1.1.2. Increasing investment in orphan drug and advanced therapy development
3.1.1.3. Growth in precision medicine, biomarker research, and genomic-based clinical studies
3.1.2. Restraints
3.1.2.1. Difficulty in patient recruitment due to small and geographically dispersed patient populations
3.1.2.2. High clinical trial costs and long development timelines
3.1.3. Opportunity
3.1.3.1. Expansion of gene therapy and cell therapy clinical research
3.1.3.2. Increasing adoption of decentralized and patient-centric clinical trial models
3.1.3.3. Growth in public-private partnerships and rare disease research collaborations
3.1.4. Trends
3.1.4.1. Increasing use of artificial intelligence and real-world evidence in trial design and patient identification
3.1.4.2. Rising focus on adaptive trial designs and platform-based clinical studies
3.1.5. Impact Analysis
4. Industry Analysis
4.1. Porter's Five Force Analysis – Global Rare Disease Clinical Trials Market
4.2. Geopolitical & Supply Chain Exposure
4.2.1. Clinical Trial Infrastructure and Site Concentration Risks
4.2.2. Regulatory and Cross-Border Patient Enrollment Challenges
4.2.3. Data Sovereignty and Clinical Data Transfer Restrictions
4.3. Social & Patient-Centric Factors
4.3.1. Patient Recruitment Challenges in Rare Disease Populations
4.3.2. Patient Advocacy Group Influence on Trial Design
4.3.3. Treatment Access and Trial Participation Awareness
4.4. Economic Factors
4.4.1. High R&D Cost Structure for Rare Disease Therapeutics
4.4.2. Funding Dependence on Pharma, Government, and Grants
4.4.3. Currency Fluctuations Impacting Global Trial Operations
4.5. Pricing Analysis
4.5.1. Orphan Drug Pricing Models
4.5.2. Clinical Trial Funding and Partnership Agreements
4.5.3. Value-Based Pricing and Reimbursement Dependencies
4.6. Regulatory Analysis
4.6.1. Orphan Drug Designation Pathways
4.6.2. Accelerated Approval and Breakthrough Therapy Pathways
4.6.3. Post-Trial Safety Monitoring and Pharmacovigilance
4.6.4. lobal Regulatory Harmonization
4.7. Go-To-Market (GTM) Strategy
4.7.1. Strategic Partnerships with Hospitals and Specialty Centers
4.8. Innovation & R&D Trends
4.8.1. Gene Therapy and Cell Therapy Clinical Development
4.8.2. Precision Medicine and Biomarker-Driven Trials
4.8.3. Real-World Evidence Integration in Trial Design
4.9. Sustainability and ESG Analysis
4.9.1. Ethical Patient Recruitment Practices
4.9.2. Diversity and Inclusion in Clinical Trial Populations
4.10. Clinical Trial Ecosystem Participants
4.10.1. Pharmaceutical and Biotech Sponsors
4.10.2. Contract Research Organizations
4.10.3. Diagnostic and Biomarker Testing Providers
4.10.4. Hospitals, Specialty Clinics, and Research Institutes
4.11. Buyer Decision Criteria & Adoption Drivers
4.11.1. Access to Rare Disease Patient Populations
4.11.2. Clinical Expertise in Complex Disease Biology
4.11.3. Advanced Scientific Capabilities and Trial Success Rates
4.12. DMI Opinion – Strategic Outlook for the Global Rare Disease Clinical Trials Market
5. By Clinical Trials Phase
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical Trials Phase
5.1.2. Market Attractiveness Index, By Clinical Trials Phase
5.2. Phase I*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Phase II
5.4. Phase III
5.5. Phase IV
6. By Therapeutic Area
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
6.1.2. Market Attractiveness Index, By Therapeutic Area
6.2. Oncology*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Neurology
6.4. Genetic Disorders
6.5. Hematology
6.6. Metabolic Disorders
6.7. Immunology
6.8. Others
7. By Study Design
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Design
7.1.2. Market Attractiveness Index, By Study Design
7.2. Interventional *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Observational
7.4. Expanded Access
7.5. Registry-based
8. By Sponsor
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sponsor
8.1.2. Market Attractiveness Index, By Sponsor
8.2. Pharmaceutical Companies*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Biotechnology Companies
8.4. Contract Research Organizations (CROs)
8.5. Academic & Medical Research Institutes
8.6. Government & Public Health Organizations
8.7. Patient Advocacy Organizations
9. By Patient Recruitment
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Recruitment
9.1.2. Market Attractiveness Index, By Patient Recruitment
9.2. Hospital-based *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Patient Registry
9.4. Digital & Social Media
9.5. Community-based
9.6. Telehealth-enabled
10. By Innovation
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Innovation
10.1.2. Market Attractiveness Index, By Innovation
10.2. Biomarker based *
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Genomic based
10.4. Precision Medicine based
10.5. Cell & Gene Therapy based
10.6. Regenerative Medicine based
10.7. Proteomics based
10.8. Metabolomics based
10.9. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical Trials Phase
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Design
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sponsor
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Recruitment
11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Innovation
11.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.9.1. US
11.2.9.2. Canada
11.2.9.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical Trials Phase
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Design
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sponsor
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Recruitment
11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Innovation
11.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.9.1. Germany
11.3.9.2. United Kingdom
11.3.9.3. France
11.3.9.4. Italy
11.3.9.5. Spain
11.3.9.6. Netherlands
11.3.9.7. Switzerland
11.3.9.8. Sweden
11.3.9.9. Norway
11.3.9.10. Denmark
11.3.9.11. Belgium
11.3.9.12. Poland
11.3.9.13. Austria
11.3.9.14. Ireland
11.3.9.15. Portugal
11.3.9.16. Greece
11.3.9.17. Finland
11.3.9.18. Rest of Europe
11.4. Latin America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical Trials Phase
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Design
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sponsor
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Recruitment
11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Innovation
11.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.9.1. Brazil
11.4.9.2. Argentina
11.4.9.3. Mexico
11.4.9.4. Chile
11.4.9.5. Colombia
11.4.9.6. Peru
11.4.9.7. Rest of Latin America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical Trials Phase
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Design
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sponsor
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Recruitment
11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Innovation
11.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.9.1. China
11.5.9.2. Japan
11.5.9.3. India
11.5.9.4. South Korea
11.5.9.5. Australia
11.5.9.6. New Zealand
11.5.9.7. Singapore
11.5.9.8. Malaysia
11.5.9.9. Thailand
11.5.9.10. Indonesia
11.5.9.11. Vietnam
11.5.9.12. Philippines
11.5.9.13. Taiwan
11.5.9.14. Rest of Asia Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Clinical Trials Phase
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Study Design
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sponsor
11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Recruitment
11.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Innovation
11.6.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.6.9.1. Saudi Arabia
11.6.9.2. United Arab Emirates
11.6.9.3. Qatar
11.6.9.4. Kuwait
11.6.9.5. Oman
11.6.9.6. Bahrain
11.6.9.7. South Africa
11.6.9.8. Egypt
11.6.9.9. Nigeria
11.6.9.10. Morocco
11.6.9.11. Rest of Middle East & Africa
12. Competitive Landscape Analysis
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
12.4. Partner Identification Analysis
12.5. Investment & Funding Landscape
12.6. Strategic Alliances & Innovation Pipelines
13. Company Profiles
13.1. Takeda Pharmaceutical Company Limited*
13.1.1. Company Overview
13.1.2. Product Portfolio
13.1.3. Revenue Analysis
13.1.4. Pricing Analysis
13.1.5. SWOT Analysis
13.1.6. Recent Developments
13.1.6.1. Major Deals
13.1.6.2. M&A
13.1.6.3. Collaboration
13.1.6.4. Acquisition
13.1.6.5. Joint Ventures
13.1.6.6. Innovations
13.1.7. Recent News
13.1.7.1. Events
13.1.7.2. Conferences
13.1.7.3. Symposiums
13.1.7.4. Webinars
13.2. F. Hoffmann-La Roche Ltd.
13.3. Pfizer Inc.
13.4. AstraZeneca
13.5. Novartis AG
13.6. Labcorp
13.7. IQVIA
13.8. ICON plc
13.9. Parexel International (MA) Corporation
13.10. Syneos Health (LIST NOT EXHAUSTIVE )
14. Global Rare Disease Clinical Trials Market – Research Methodology
14.1. Research Data
14.1.1. Secondary Data
14.1.2. Primary Data
14.1.3. CAGR Analysis
14.2. Market Size Estimation Methodology
14.2.1. Bottom-Up Approach
14.2.2. Top-Down Approach
14.3. Market Breakdown & Data Triangulation
14.4. Research Assumptions
14.5. Limitations
15. Appendix
15.1. About Us and Services
15.2. Contact Us

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us